Basic Information
Infanrix Hexa
Regulatory Information
EMEA/H/C/000296
October 23, 2000
June 29, 2000
48
September 4, 2024
Company Information
Belgium
Rue de l'Institut, 89 B-1330 Rixensart
GlaxoSmithKline Biologicals SA
Active Substances Detail
Diphtheria toxoidtetanus toxoidBordetella pertussis antigens (pertussis toxoid, filamentous haemagglutinin, pertactin)hepatitis B surface antigenpoliovirus (inactivated) (type-1 (Mahoney strain), type-2 (MEF-1 strain), type-3 (Saukett strain))Haemophilus influenzae type b polysaccharide
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Infanrix hexa is indicated for primary and booster vaccination of infants from the age of 6 weeks and toddlers against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and disease caused by Haemophilus influenzae type b. The use of Infanrix hexa should be in accordance with official recommendations.
Overview Summary
Infanrix hexa is a vaccine used to protect infants from six weeks of age and toddlers against diphtheria, tetanus, pertussis (whooping cough), hepatitis B, poliomyelitis (polio) and diseases such as bacterial meningitis caused by the bacterium Haemophilus influenzae type b (Hib). Infanrix hexa contains the following active substances: - toxoids (chemically weakened toxins) from diphtheria and tetanus; - parts of Bordetella pertussis (pertussis, a bacterium that causes whooping cough); - parts of the hepatitis B virus; - inactivated polioviruses; - polysaccharides (sugars) from Hib.